Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

09/11/2023 5:04 PMEDT

Press
Releases

08/31/2023

Pardes Biosciences Announces Closing of Tender Offer

07/17/2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Webcasts

Financial Information

Document Date	Description	Form	View
12/31/2021	Annual report which provides a comprehensive overview of the company for the past year	10-K	View HTML 0000950170-22-004946.pdf 0000950170-22-004946.rtf 0000950170-22-004946.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
12/31/2022	Annual report which provides a comprehensive overview of the company for the past year	10-K	View HTML 0000950170-23-007860.pdf 0000950170-23-007860.rtf 0000950170-23-007860.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
03/31/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-027060.pdf 0001213900-21-027060.rtf 0001213900-21-027060.xls EX-101.INS - XBRL INSTANCE FILE
06/30/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-042747.pdf 0001213900-21-042747.rtf 0001213900-21-042747.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
09/30/2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001213900-21-058296.pdf 0001213900-21-058296.rtf 0001213900-21-058296.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
03/31/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-008983.pdf 0000950170-22-008983.rtf 0000950170-22-008983.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
06/30/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-017368.pdf 0000950170-22-017368.rtf 0000950170-22-017368.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
09/30/2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-22-022581.pdf 0000950170-22-022581.rtf 0000950170-22-022581.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
03/31/2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-23-018303.pdf 0000950170-23-018303.rtf 0000950170-23-018303.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
06/30/2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0000950170-23-038555.pdf 0000950170-23-038555.rtf 0000950170-23-038555.xls EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Contact
IR

Send us an investor-related question using the form below.